ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2867

Aberrant Epigenetic Alterations at the Promoter up-Regulate cAMP Responsive Element Modulator Alpha in CD4+ T Cells from Patients with Systemic Lupus Erythematosus

Qing Zhang1, Huilin Zhang2, Shu Ding3, Hai Long4, Yi Zhan2, Xiangning Qiu4 and Qianjin Lu4, 1Department of Dermatology, The Second Xiangya Hospital of Central South University, Changsha, China, 2Second Xiangya Hospital, Central South University, Changsha, China, 3Department of Dermatology, The Third Xiangya Hospital of Central South University, Changsha, China, 4Department of Dermatology, Second Xiangya Hospital, Central South University, Changsha, China

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: DNA Methylation, Histone Modification and systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 15, 2016

Title: Systemic Lupus Erythematosus – Human Etiology and Pathogenesis - Poster II

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:  Recently, accumulating studies have documented that up-regulated cAMP responsive element modulator α (CREMα) which can inhibit IL-2 and induce IL-17A in T cells plays a critical role in the pathogenesis of systemic lupus erythematosus (SLE). The aim of this research is to investigate the mechanisms that regulate CREMα expression in SLE.

Methods:  Histone H3 lysine 4 trimethylation (H3K4me3, a hallmark correlated with transcription activation) amounts at various gene promoters in CD4+ T cells from SLE patients and healthy controls were assayed by chromatin immunoprecipitation (ChIP) microarray. Numbers of H3K4me3, H3K4 methyltransferases SET domain containing 1 (Set1) and mixed-lineage leukemia 1 (MLL1), H3ac and H4ac (both are marks of gene activation), and DNA methyltransferase (DNMT) 3a within the CREMα promoter were measured by ChIP and real-time PCR. DNA methylation (a hallmark of gene silencing) abundance at the CREMα promoter was tested by methylated CpG-DNA immunoprecipitation (MeDIP) and real-time PCR. Levels of CREMα and Set1 mRNA and protein were quantified by real-time RT-PCR and western blotting, respectively. IL-2 and IL-17A productions were detected by enzyme-linked immunosorbent assay (ELISA).

Results:  From the ChIP microarray data, we found sharply increased H3K4me3 amount at the CREMα promoter in SLE CD4+ T cells compared to controls. Then by ChIP and real-time PCR, we confirmed this result. Moreover, H3K4me3 amount at the promoter was positively correlated with CREMα mRNA level in SLE CD4+ T cells. In addition, a striking increase was observed in Set1 enrichment, but no marked change in MLL1 enrichment at the CREMα promoter in SLE CD4+ T cells. We also proved Set1 enrichment was positively correlated with H3K4me3 amount at the CREMα promoter, and positively correlated with CREMα mRNA level in SLE CD4+ T cells. Knocking down Set1 with siRNA in SLE CD4+ T cells decreased Set1 and H3K4me3 enrichments, and elevated the levels of DNMT3a and DNA methylation, while the amounts of H3ac and H4ac didn’t alter greatly at the CREMα promoter. All these inhibited the expression of CREMα, then augmented IL-2 and down-modulated IL-17A productions. Subsequently, we observed that DNMT3a enrichment at the CREMα promoter was down-regulated significantly in SLE CD4+ T cells, and H3K4me3 amount was negatively correlated with both DNA methylation level and DNMT3a enrichment at the CREMα promoter in SLE CD4+ T cells.

Conclusion:  Our findings suggest for the first time that in SLE CD4+ T cells, increased Set1 enrichment up-regulates H3K4me3 amount at the CREMα promoter, which antagonizes DNMT3a and suppresses DNA methylation within this region. All these factors induce CREMα overexpression, consequently result in IL-2 under-expression and IL-17A overproduction, and contribute to the development of SLE at last.


Disclosure: Q. Zhang, None; H. Zhang, None; S. Ding, None; H. Long, None; Y. Zhan, None; X. Qiu, None; Q. Lu, None.

To cite this abstract in AMA style:

Zhang Q, Zhang H, Ding S, Long H, Zhan Y, Qiu X, Lu Q. Aberrant Epigenetic Alterations at the Promoter up-Regulate cAMP Responsive Element Modulator Alpha in CD4+ T Cells from Patients with Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/aberrant-epigenetic-alterations-at-the-promoter-up-regulate-camp-responsive-element-modulator-alpha-in-cd4-t-cells-from-patients-with-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/aberrant-epigenetic-alterations-at-the-promoter-up-regulate-camp-responsive-element-modulator-alpha-in-cd4-t-cells-from-patients-with-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology